| Literature DB >> 35034351 |
Craig R Lee1, Jasmine A Luzum2, Katrin Sangkuhl3, Roseann S Gammal4,5, Marc S Sabatine6, Charles Michael Stein7, David F Kisor8, Nita A Limdi9, Yee Ming Lee10, Stuart A Scott11,12, Jean-Sébastien Hulot13, Dan M Roden14, Andrea Gaedigk15, Kelly E Caudle5, Teri E Klein3, Julie A Johnson16, Alan R Shuldiner17.
Abstract
CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition and increased risk for major adverse cardiovascular and cerebrovascular events. This guideline is an update to the 2013 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of clopidogrel based on CYP2C19 genotype and includes expanded indications for CYP2C19 genotype-guided antiplatelet therapy, increased strength of recommendation for CYP2C19 intermediate metabolizers, updated CYP2C19 genotype to phenotype translation, and evidence from an expanded literature review (updates at www.cpicpgx.org).Entities:
Mesh：
Substances：
Year: 2022 PMID： 35034351 PMCID： PMC9287492 DOI： 10.1002/cpt.2526
Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.903